louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01528124: A Study of LY3025876 in Healthy Volunteers
Official title: A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3025876 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2012-02-07
Enrollment: 41
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This trial is conducted in Singapore. The aim of this trial is to evaluate the safety and tolerability of the study drug in healthy people and investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.


Eligibility criteria: Inclusion Criteria:

* Must be either a healthy male or a healthy female who cannot become pregnant
* Have a body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m\^2), inclusive, at screening

Exclusion Criteria:

* Are allergic to LY3025876 or related compounds
* Have a history of significant disease that may affect the actions of drugs or may pose a risk when taking the study medication
* Have a history of developing allergies, asthma, severe drug allergies (symptoms including, but not limited to, itching, red rashes, sores on the skin, scaling and shedding of skin), allergies or reactions to more than one drug, or have had bad reactions to skin creams containing corticosteroids. Corticosteroids are mainly used to control inflammation.

Primary outcomes:
measure: Number of Participants With 1 or More Drug-related Adverse Events or Any Serious Adverse Events
timeFrame: Baseline up to 28 days post-dose
Secondary outcomes:
measure: Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3025876
timeFrame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose
measure: Pharmacokinetics: Maximum Concentration (Cmax) of LY3025876
timeFrame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose
measure: Number of Participants Developing Anti-LY3025876 Antibodies
timeFrame: Day 28 post-dose
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT01334424: Oxidative Stress in Robot-assisted Laparoscopic Radical Prostatectomy
Official title: Oxidative Stress in Robot-assisted Laparoscopic Radical Prostatectomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Oxidative Stress
Keywords: Robot assisted laparoscopic radical prostatectomy
Hypoperfusion reperfusion injury,
Propofol
oxidative stress
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2011-04-13
Enrollment: 40
Sex: MALE
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: Gut hypoperfusion - reperfusion injury is an unavoidable event at the end of laparoscopic surgery. It produces oxidative stress (reactive oxygen species). Malondialdehyde have been demonstrated to be a reliable biomarker for the evaluation of oxidative stress in vivo. Propofol (2, 6 - diisopropylphenol), a highly liposoluble anaesthetic, has a potent antioxidant activity against lipid peroxidation in both in vitron and in vivo studies. On the basis of this knowledge, the investigators hypothesized that propofol has preventive effect for gut hypoperfusion - reperfusion induced injury in robot-assisted laparoscopic radical prostatectomy.

Detailed description: Increased intrabdominal pressure is associated with pneumoperitoneum for laparoscopic procedures and is one of the main factors in impairment of splanchnic perfusion by compressing vessels. An hypoperfusion - reperfusion human model is observed during and soon after laparoscopic surgery. After deflation of the abdomen, intrabdominal pressure and splanchnic blood flow normalize, representing reperfusion.

Reactive oxygen species is produced in metabolic and physiologic processes, and harmful oxidative reactions may occur in organisms that remove them via enzymatic and nonenzymatic antioxidative mechanisms.

Propofol (2, 6 - diisopropylphenol), a highly liposoluble anaesthetic, has a potent antioxidant activity against lipid peroxidation in both in vitron and in vivo studies. Propofol also attenuates ischemia - reperfusion induced lipid peroxidation in humans. On the basis of this knowledge, we hypothesized that propofol has preventive effect for gut hypoperfusion - reperfusion induced injury in robot-assisted laparoscopic radical prostatectomy.

Eligibility criteria: Inclusion Criteria:

* patients receiving robot-assisted laparoscopic radical prostatectomy in ASA II-III physical status

Exclusion Criteria:

* history of sepsis or shock, clinically relevant cardiopulmonary disease, persistent tobacco abuse, recent antioxidant or vasoconstrictor use

Primary outcomes:
measure: Amount of Malondialdehyde in plasma
timeFrame: one day
Secondary outcomes:
Other outcomes:
Locations:
city: Tao-Yuan
country: Taiwan
facility: Dept. of Anesthesiology, Chang Gung Memorial Hospital
Study officials:
affiliation: Dept. of Anesthesiology, Chang Gung Memorial Hospital
name: Chiao-Fen Luo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02351024: Phase I Study PK Study With OXP005 and Naprosyn
Official title: Study to Assess the Comparative Bioavailability and Pharmacokinetics of Naproxen From OXP005 Tablets (Test) And Naprosyn® Tablets (Reference) in Normal, Healthy, Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pharmacokinetics
Lead sponsor: Oxford Pharmascience Ltd
Sponsor class: INDUSTRY
First posted: 2015-01-30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes

Brief summary: The Sponsor is developing a new form of naproxen (the study drug, OXP005), for the potential treatment of rheumatic and painful conditions. The study will compare the study drug to an already marketed formulation of prescription strength naproxen (Naprosyn® the reference product) by looking at how a single dose of the drug is taken up by the body. The safety and tolerability of the drug will also be assessed.


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects and non-pregnant, non breast feeding healthy female subjects aged 18 to 55 years
* Body mass index 18.0 to 30.0 kg/m2

Exclusion Criteria:

* History of or current significant diseases or conditions including any disease or condition affecting the haematopoietic, cardiovascular, renal, hepatic, endocrine, pulmonary, central nervous, immunological, dermatological, gastrointestinal or any other body system

Primary outcomes:
measure: Comparative bioavailability of naproxen as measured by Tmax, Cmax, AUC, half-life
timeFrame: Day 1 & Day 8 single dose crossover
Secondary outcomes:
Other outcomes:
Locations:
city: Nottingham
country: United Kingdom
facility: Quotient Clinical Ltd
Study officials:
References:
Clinical trial NCT01838824: Applying Speed of Processing Training to Individuals With Multiple Sclerosis
Official title: Applying Speed of Processing Training (SPT) to Individuals With Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Keywords: Processing Speed
Intervention
Multiple Sclerosis
Cognition
Lead sponsor: Kessler Foundation
Sponsor class: OTHER
Collaborators: name: National Multiple Sclerosis Society
First posted: 2013-04-24
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This pilot study will document the efficacy of a behavioral intervention for Processing Speed (PS) in Multiple Sclerosis (MS), Speed of Processing Training (SPT), which has been successful used in the aging population in several studies. This study will (1) apply a treatment protocol for PS impairments, well-validated in aging, to persons with MS with impaired PS, and document its efficacy on standard neuropsychological (NP) tests (2) assess the effectiveness of the intervention utilizing global measures of daily life, including an objective measure (TIADL) (3) examine the long term impact of SPT. This study is unique in that it will be the first to evaluate the efficacy of a highly-manualized structured behavioral treatment for processing speed deficits in persons with MS utilizing the optimal methodology for carrying out such studies, a randomized clinical trial. Given the prevalence of PS deficits in the MS population and the significant impact such deficits have on everyday functioning, public safety, and overall quality of life, the identification of an effective intervention for PS deficits in MS could have a profound impact on the population and society as a whole.


Eligibility criteria: Inclusions:

* diagnosis of Multiple Sclerosis
* fluent in English
* processing speed impairment (based on evaluation).

Exclusions:

* currently taking steroids and /or benzodiazepines
* prior stroke or neurological disease
* history of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder, Schizophrenia, Bipolar Disorder I or II
* significant alcohol or drug abuse history

Primary outcomes:
measure: Change in scores on standardized tests of processing speed
timeFrame: Three points in time: Baseline (week 1), immediately following treatment (Group 1 - week 7, Group 2 - week 13), long-term follow-up (Group 1 - week 13, Group 2 - Week 19)
Secondary outcomes:
Other outcomes:
Locations:
city: West Orange
country: United States
facility: Kessler Foundation
state: New Jersey
Study officials:
affiliation: Kessler Foundation
name: Nancy Chiaravalloti, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04397224: Reduction or Extension of COnduction Time With Ventricular Electromechanical Remodeling (RECOVER)
Official title: Prospective Multicenter Observation Study on the Serial Changes in Ventriculo-ventricular Conduction Times According to Cardiac-resynchronization Therapy Response
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Failure
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
Collaborators: name: Abbott Medical Devices
First posted: 2020-05-21
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Heart failure patients implanted with multipoint pacing CRT device and quadripolar left ventricular lead from Abbott

Brief summary: This prospective multicenter registry study aims to detect the serial changes in ventriculo-ventricular conduction times according to cardiac-resynchronization therapy response.


Eligibility criteria: Inclusion Criteria:

* meeting the current ESC or ACCF/AHA/HRS Class I or Class IIa indications for cardiac-resynchronization (CRT) implant

Exclusion Criteria:

* Myocardial infarction, unstable angina within 40 days prior the enrollment
* Recent cardiac revascularization in the 4 weeks prior to the enrollment or planned for the 3 months following
* Cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months prior to the enrollment
* Primary valvular disease requiring surgical correction
* Pregnant or are planning during the duration of the investigation
* Status 1 candidate for cardiac transplantation or consideration for transplantation over the next 12 months
* Post-cardiac transplantation
* Life expectancy \< 12 months
* Currently participating in any other clinical investigation except for observational registry

Primary outcomes:
measure: Serial change of ventriculo-ventricular conduction times
timeFrame: from enrollment to last follow-up (2 years)
Secondary outcomes:
Other outcomes:
Locations:
city: Bucheon
country: Korea, Republic of
facility: Sejong General Hospital
city: Changwon
country: Korea, Republic of
facility: Samsung Changwon Medical Center
city: Daejeon
country: Korea, Republic of
facility: Chungnam National University Hospital
city: Daejeon
country: Korea, Republic of
facility: Eulji University Hospital
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
References:
Clinical trial NCT02982824: Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy
Official title: Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Drug Resistant Epilepsy
Keywords: Children
IQ
Idiopathic epilepsy
Magnesium supplementation
Seizure control
Chalfont score
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2016-12-06
Enrollment: 60
Sex: ALL
Minimum age (years): 6
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Effect of oral magnesium sulfate (Mg) supplementation will be studied. Children with drug resistant idiopathic epilepsy following up in Pediatric Neurology Clinic, Ain Shams University, will be randomized to either Mg add-on treatment group or anti-epileptic drugs AEDs alone. Serum magnesium, seizure control and Intelligent quotation (IQ) will be done at base line and after 6 months of treatment.

Detailed description: The Aim of this work was to study the effect of Magnesium as add on therapy on clinical seizure control in drug resistant idiopathic epilepsy and IQ.

Eligibility criteria: Inclusion Criteria:

* Children with drug resistant idiopathic epilepsy

Exclusion Criteria:

* Structural, Metabolic, Infectious and Unknown etiology epilepsy
* Any neurological disease other than epilepsy
* Any nutritional disorder
* Any other systemic diseases (including Renal disease, Cardiac arrhythmia)
* Drug intake other than antiepileptic drugs (AED)

Primary outcomes:
measure: Seizure control
timeFrame: 6 months
measure: IQ improvement
timeFrame: 6-months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Children's Hospital, Faculty of Medicine, Ain Shams University
Study officials:
affiliation: Pediatrics, Faculty of Medicine, Ain Shams University
name: Sahar MA Hassanein, PhD. MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gontijo-Amaral C, Ribeiro MA, Gontijo LS, Condino-Neto A, Ribeiro JD. Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial. Eur J Clin Nutr. 2007 Jan;61(1):54-60. doi: 10.1038/sj.ejcn.1602475. Epub 2006 Jun 21.
citation: Osborn KE, Shytle RD, Frontera AT, Soble JR, Schoenberg MR. Addressing potential role of magnesium dyshomeostasis to improve treatment efficacy for epilepsy: A reexamination of the literature. J Clin Pharmacol. 2016 Mar;56(3):260-5. doi: 10.1002/jcph.626. Epub 2015 Oct 26.
Clinical trial NCT06039124: Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
Official title: Subsequent Bevacizumab Treatment in Patients With HHT After the End of BABH Interventional Study. A Descriptive Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemorrhagic Hereditary Telangiectasia
HHT
Keywords: HHT
VEGF therapy
BEVACIZUMAB
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2023-09-15
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients included in the BABH study (adults, with a confirmed diagnosis of Rendu-Osler disease, presenting with bleeding requiring regular transfusions).

Brief summary: Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT.

We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study recently published (NCT03227263, J Int Med 2023). In this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. The duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment.

We describe the evolution of the number of RBC transfused in HHT patients who received bevacizumab during the year after the end of the study.


Eligibility criteria: Inclusion Criteria:

* Patient included in BABH study

Exclusion Criteria:

* Patients opposition

Primary outcomes:
measure: Bevacizumab treatment description after end of BABH study
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: Service de Médecine Interne et Maladies Vasculaires + Service Neuropédiatrie et neurochirurgie de l'enfant - CHU Angers
city: Boulogne Billancourt
country: France
facility: Hôpital Ambroise Paré
city: Montpellier
country: France
facility: CHU de Montpellier-Hôpital St Eloi
Study officials:
affiliation: Hospices Civils de Lyon
name: Sophie DUPUIS-GIROD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02185924: Combination of Continuous Femoral Block and Intravenous Parecoxib For Postoperative Analgesia After Total Knee Arthroplasty
Official title: COMBINATION OF CONTINUOUS FEMORAL BLOCK AND INTRAVENOUS PARECOXIB FOR POSTOPERATIVE ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY. A DOUBLE BLIND PROSPECTIVE STUDY.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: POSTOPERATIVE ANALGESIA FOR TKA PARECOXIB/CFB
Keywords: PARECOXIB
CONTINUOUS FEMORAL BLOCK
Lead sponsor: Asklepieion Voulas General Hospital
Sponsor class: OTHER_GOV
First posted: 2014-07-10
Enrollment: 90
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Combination of continuous femoral block with parEcoxib vs placebo. Investigation of morphine consumption, opioid sparing effects, VAS pain scores, haemodynamics, Anxierty scores, transfusion requirements , Range of motion and rehabilitation parameters between two groups


Eligibility criteria: Inclusion Criteria:

* PATIENTS ASA I-II UNDERGOING TOTAL KNEE ATRTHROPLASTY

Exclusion Criteria:

Exclusion criteria for both groups included:

* Age younger than 40 years old or older than 80 years old
* ASA \> III
* Obesity (\>140 kg body weight)
* Allergy to local anesthetics
* History dependence on opioids
* Contraindications for subarachnoid anesthesia or femoral block (coagulopathy, local infection, pre-existing neurological problems, patient refusal)
* Contraindications to the administration of parecoxib
* Severe hepatic or renal disease (serum creatinine ≥ 1.7 mg/dl)

Primary outcomes:
measure: MORPHINE CONSUMPTION WITH PCA BETWEEN TWO GROUPS
timeFrame: 36/h POSTOPERATIVELY
measure: VAS PAIN SCORES BETWEEN TWO GROUPS
timeFrame: 36/h POSTOPERATIVELY
measure: HAEMODYNAMIC PARAMETERS BETWEEN TWO GROUPS
timeFrame: During perioperative period
Secondary outcomes:
measure: ANXIETY LEVELS
timeFrame: 36 HOURS POSTOPERATIVELY
Other outcomes:
measure: RANGE OF MOTION, TRANSFUSION REQUIREMENTS, VAS SCORES POSTOPERATIVELY
timeFrame: AFTER 36 HOURS POSTOPERATIVELY
measure: MODIFIED BROMAGE SCALE
timeFrame: 36/h POSTOPEPATIVELY
Locations:
city: Voula Athens
country: Greece
facility: Department of Anaesthesia Asklepeion Voulas General Hospital
Study officials:
affiliation: SENIOR CLINICAL FELLOW THE ROYAL BROMPTON AND HAREFIELD TRUST, SENIOR REGISTRAR IN ANAESTHESIA ASKLEPEION VOULAS
name: DESPOINA SARRIDOU, SENIOR REGISTRAR
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sarridou DG, Chalmouki G, Braoudaki M, Siafaka I, Asmatzi C, Vadalouka A. Parecoxib Possesses Anxiolytic Properties in Patients Undergoing Total Knee Arthroplasty: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Clinical Study. Pain Ther. 2016 Jun;5(1):55-62. doi: 10.1007/s40122-016-0046-1. Epub 2016 Feb 9.
Clinical trial NCT05792124: Comparison of the Effects of Retro Laminar Block (RLB) and Erector Spina Area Block (ESP) on Postoperative Recovery Quality and Pain in Lumbar Spinal Surgery
Official title: Comparison of the Effects of Retro Laminar Block (RLB) and Erector Spina Area Block (ESP) on Postoperative Recovery Quality and Pain in Lumbar Spinal Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Postoperative Pain
Keywords: Recovery Quality
postoperative pain
Erector spina plane block
Retrolaminar block
Lead sponsor: Aydin Adnan Menderes University
Sponsor class: OTHER
First posted: 2023-03-31
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare the efficacy of erector spinae plane block (ESPB) and Retrolaminar Block on postoperative recovary quality and pain after lumbar spinal surgery

Detailed description: The study was designed as a double-blind, prospective randomized controlled trial.

Blindness; The healthcare professionals who will monitor the patient's pain in the post-operative period will not know which of the ESP or RLB block is applied. Randomization of the patients was planned using computer aided. It was envisaged to include 40 participants each in the ESP block and RLB block groups. The current pain status of the patients in the ESP block and RLB block groups in the postoperative period was determined by NRS (Numerical rating scale) at rest and motion at certain hour intervals (30 .min,1.,6.,12.,24. hours) will be done, when the patients' NRS scores are 4 and above, an additional intravenous analgesic will be administered and the number of bolus doses with PCA in the first 24 hours will be recorded. The recovery quality of the patients who underwent both ESP block and RLB block at the postoperative 24th hour will be evaluated with a (QoR-40) scoring system. In addition, the hemodynamic values of the patients will be recorded in these intervals.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing lumbar spinal surgery under elective conditions
* ASA I-III
* Between 18-75 ages

Exclusion Criteria:

* refuse during registration
* request to be dismissed from study
* failure to give informed consent
* emergency surgery
* bleeding diathesis
* Presence of contraindications to the LA agents used in this study chronic use of opioids psychiatric disorders the presence of infection at the injection site

Primary outcomes:
measure: Qor-40 test (The recovery quality test)
timeFrame: 24th hour
Secondary outcomes:
measure: NRS (Numerical rating scale)
timeFrame: 30 minutes,1st hour,6th hour,12th hour and 24th hour
measure: Postoperative pain
timeFrame: 30 minutes,1st hour,6th hour,12th hour and 24th hour
Other outcomes:
Locations:
city: Aydın
country: Turkey
facility: Adnan Menderes University Faculty of Medicine
Study officials:
References: